ADT Use Not Linked to Dementia in Prostate Cancer

Excerpt:

“For men with prostate cancer, use of androgen deprivation therapy (ADT) seems not to be associated with dementia, according to a study published online Nov. 21 in the Journal of Clinical Oncology.

“Farzin Khosrow-Khavar, Ph.D., from McGill University in Hamilton, Canada, and colleagues examined whether use of ADT is associated with increased risk of dementia, including Alzheimer’s disease. A cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer from April 1, 1988, to April 30, 2015 were recruited and followed until April 30, 2016. To account for delays associated with dementia diagnosis and minimize reverse causality, ADT exposure was lagged by one year.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Common Prostate Cancer Treatment Linked to Later Dementia

Excerpt:

“A new retrospective study of patient medical records suggests that men with prostate cancer who are treated with testosterone-lowering drugs are twice as likely to develop dementia within five years as prostate cancer patients whose testosterone levels are not tampered with.

“The study, by researchers at the Stanford University School of Medicine and the University of Pennsylvania Perelman School of Medicine, also demonstrates emerging techniques for extracting biomedical data from ordinary patient medical records.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Lifeline service.